Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs.

Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again.

As of Thursday, July 24, Sarepta Therapeutics, Inc.’s SRPT share price has dipped by 18.81%, which has investors questioning if this is right time to buy.

Arrowhead Pharmaceuticals Inc. said Monday that it’s owed a $100 million milestone payment from Sarepta Therapeutics Inc. within the next two months, pressuring the beleaguered biotech company just ...

Arrowhead Pharmaceuticals (ARWR) Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (SRPT).

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was triggered when ...

As of Monday, July 28, Sarepta Therapeutics, Inc.’s SRPT share price has surged by 5.74%, which has investors questioning if this is right time to sell.

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics July 24, 2025 | 6 min read ...

Arrowhead Pharmaceuticals fell by 12.23 percent on Monday to close at $14.71 apiece as investors turned cautious amid regulatory troubles faced by one of its partners, Sarepta Therapeutics. Last ...